Your browser doesn't support javascript.
loading
Evaluation of HZX-960, a novel DCN1-UBC12 interaction inhibitor, as a potential antifibrotic compound for liver fibrosis.
Zhou, Wenjuan; Dong, Guanjun; Gao, Ge; He, Zhangxu; Xu, Jiale; Aziz, Shireen; Ma, Liying; Zhao, Wen.
Afiliação
  • Zhou W; State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Ins
  • Dong G; Department of Pathology, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo 0379, Norway.
  • Gao G; State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Ins
  • He Z; State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Ins
  • Xu J; State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Ins
  • Aziz S; State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Ins
  • Ma L; State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Ins
  • Zhao W; State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Ins
Biochem Cell Biol ; 100(4): 309-324, 2022 08 01.
Article em En | MEDLINE | ID: mdl-35544948
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzimas de Conjugação de Ubiquitina / Ubiquitina-Proteína Ligases / Inibidores Enzimáticos / Cirrose Hepática Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Biochem Cell Biol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzimas de Conjugação de Ubiquitina / Ubiquitina-Proteína Ligases / Inibidores Enzimáticos / Cirrose Hepática Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Biochem Cell Biol Ano de publicação: 2022 Tipo de documento: Article